FBDD: Examples

Many examples of fragment-based approaches have been described in the literature. Here's a sampling, organised by institution:

Astex
Howard et al, Fragment-Based Discovery of the Pyrazol-4-yl Urea (AT9283), a Multitargeted kinase Inhibitor with Potent Aurora Kinase Activity, J. Med. Chem. 2009, 52, 379-388 DOI | Dan's review

Wyatt et al, Identification of N-(4-Piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design. J. Med. Chem. 2008, 51, 4986–4999. DOI | Dan's review

Roche
Boehm et al, Novel Inhibitors of DNA Gyrase: 3D Struture Based Biased Needle Screening, Hit Validaton by Biophysical Methods, and 3D Guided Optimization. A promising Alternative to Random Screening. J. Med. Chem. 2000, 43, 2664-2674. DOI | Pete's review